Total Payments
$842.57
2023 Payments
$266.96
Companies
14
Transactions
16
Medicare Patients
3,895
Medicare Billing
$424,287
Payment Breakdown by Category
Food & Beverage$706.92 (83.9%)
Education$135.65 (16.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $706.92 | 12 | 83.9% |
| Education | $135.65 | 4 | 16.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $145.10 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $125.86 | 3 | $0 (2019) |
| Exelixis Inc. | $121.86 | 1 | $0 (2023) |
| Lilly USA, LLC | $100.39 | 1 | $0 (2021) |
| Foundation Medicine, Inc. | $99.99 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $81.90 | 1 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $59.47 | 1 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $39.19 | 1 | $0 (2017) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $12.01 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $266.96 | 2 | Genentech USA, Inc. ($145.10) |
| 2022 | $12.01 | 1 | AstraZeneca Pharmaceuticals LP ($12.01) |
| 2021 | $194.21 | 3 | Lilly USA, LLC ($100.39) |
| 2019 | $125.63 | 3 | Novartis Pharmaceuticals Corporation ($114.58) |
| 2018 | $112.28 | 2 | Foundation Medicine, Inc. ($99.99) |
| 2017 | $131.48 | 5 | Millennium Pharmaceuticals, Inc. ($59.47) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/16/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: Oncology | ||||||
| 02/15/2023 | Genentech USA, Inc. | Lunsumio (Biological) | Food and Beverage | In-kind items and services | $145.10 | General |
| Category: BioOncology | ||||||
| 06/27/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $12.01 | General |
| 08/31/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $81.90 | General |
| Category: Oncology | ||||||
| 06/02/2021 | Lilly USA, LLC | — | Education | In-kind items and services | $100.39 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/19/2019 | Novartis Pharmaceuticals Corporation | GLEEVEC (Drug) | Food and Beverage | In-kind items and services | $100.79 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2019 | PFIZER INC. | TALZENNA (Drug) | Education | In-kind items and services | $11.05 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2019 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: HEMATOLOGY | ||||||
| 05/07/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 03/07/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONFOCUS, FOUNDATIONACT | Food and Beverage | In-kind items and services | $99.99 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2017 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $10.60 | General |
| Category: Oncology | ||||||
| 03/22/2017 | Kyowa Kirin, Inc. | SANCUSO (Drug), FARESTON, IXEMPRA | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 03/11/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $59.47 | General |
| Category: Oncology | ||||||
| 03/11/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $39.19 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 908 | 1,551 | $369,476 | $105,663 |
| 2022 | 10 | 916 | 1,556 | $367,785 | $103,301 |
| 2021 | 10 | 1,043 | 1,804 | $416,143 | $119,148 |
| 2020 | 12 | 1,028 | 1,718 | $379,820 | $96,175 |
Total Patients
3,895
Total Services
6,629
Medicare Billing
$424,287
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 187 | 439 | $101,657 | $30,120 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 175 | $56,936 | $18,407 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 265 | 396 | $60,672 | $18,207 | 30.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 164 | $34,568 | $9,647 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 60 | 61 | $36,079 | $7,938 | 22.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 82 | 164 | $18,781 | $6,051 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 54 | 54 | $21,192 | $4,988 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $16,401 | $4,191 | 25.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 36 | $14,328 | $3,517 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 29 | $8,862 | $2,598 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 512 | $117,932 | $35,070 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 264 | 388 | $58,899 | $16,965 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 70 | 146 | $47,425 | $15,662 | 33.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 59 | 59 | $34,810 | $8,686 | 25.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 96 | 159 | $33,390 | $8,536 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $16,991 | $4,315 | 25.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 85 | 145 | $16,530 | $4,202 | 25.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 40 | 40 | $15,920 | $4,059 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $16,464 | $3,629 | 22.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 31 | $9,424 | $2,177 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 184 | 468 | $108,388 | $32,658 | 30.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 316 | 518 | $78,493 | $24,493 | 31.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 73 | 149 | $48,483 | $16,050 | 33.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 122 | 222 | $46,620 | $11,839 | 25.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 60 | 60 | $35,400 | $8,726 | 24.6% |
About Dr. Mian Mushtaq, M.D
Dr. Mian Mushtaq, M.D is a Hematology & Oncology healthcare provider based in Jeffersonville, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043266174.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mian Mushtaq, M.D has received a total of $842.57 in payments from pharmaceutical and medical device companies, with $266.96 received in 2023. These payments were reported across 16 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($706.92).
As a Medicare-enrolled provider, Mushtaq has provided services to 3,895 Medicare beneficiaries, totaling 6,629 services with total Medicare billing of $424,287. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jeffersonville, IN
- Active Since 05/26/2006
- Last Updated 01/20/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043266174
Products in Payments
- Lunsumio (Biological) $145.10
- CABOMETYX (Drug) $121.86
- GLEEVEC (Drug) $100.79
- FOUNDATIONONE (Device) $99.99
- OPDIVO (Biological) $81.90
- NINLARO (Drug) $59.47
- Imbruvica (Drug) $39.19
- TASIGNA (Drug) $13.79
- ADCETRIS (Biological) $12.29
- MEKINIST (Drug) $11.28
- TALZENNA (Drug) $11.05
- SANCUSO (Drug) $10.94
- IMBRUVICA (Drug) $10.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.